Skip to main content
. 2020 Apr 30;8(1):29–35. doi: 10.14791/btrt.2020.8.e10

Table 2. Recurrence and treatment.

Variables Values
Follow-up duration (month)
 Median (range) 19.9 (7–177)
Interval, initial CCRT-first recurrence (month)
 Median (range) 7.1 (1–92.7)
First recurrent tumor size (cm)
 Median (range) 5.5 (1.4–13.8)
First recurrence site
 In-field 25 (69.4)
 Out-field 4 (11.1)
 In- and out-field 7 (19.4)
Treatment at first recurrence
 Operation 4 (11.1)
 Radiotherapy 9 (25)
 Operation+radiotherapy 2 (5.6)
 Radiotherapy+chemotherapy 12 (33.3)
 Operation+chemotherapy 1 (2.8)
 Operation+radiotherapy+chemotherapy 8 (22.2)
Surgical resection
 Yes 17 (47.2)
 No 19 (52.8)
Surgical resection extent
 GTR 4 (23.5)
 NTR 7 (41.2)
 STR 6 (35.3)
MGMT methylation at surgical resection
 (+) 0 (0)
 (-) 1 (5.9)
 NA 16 (94.1)
IDH-1 at surgical resection
 (+) 0 (0)
 (-) 12 (70.6)
 NA 5 (29.4)
Ki-67 at surgical resection (%)
 Median (range) 20 (10–60)
Second recurrence
 Yes 22 (61.1)
 No 9 (25)
 NA 5 (13.9)
Treatment at second recurrence
 Yes 19 (86.4)
 No 3 (13.6)
Surgical resection at second recurrence
 Yes 6 (27.3)
 No 16 (72.7)
Re-irradiation at second recurrence
 Yes 14 (63.6)
 No 8 (36.4)
Last follow-up status
 No evidence of disease 3 (8.3)
 Alive with disease 19 (52.8)
 Death from disease 14 (38.9)

Data are presented as number (%) unless otherwise noticed. CCRT, concurrent chemoradiotherapy; GTR, gross total resection; NTR, near-total resection; STR, subtotal resection; MGMT, O6-methylguanine-DNA methyltransferase; IDH, isocitrate dehydrogenase; NA, not assessable